Cure Parkinson’s and Van Andel Institute announce funding for a phase 1 clinical trial of low-dose lithium in Parkinson’s disease - vai.org/article/cure-parkin...
"Why study lithium in Parkinson’s?
Early preclinical data suggests that lithium at very low doses may be protective against the dopamine nerve cell (neuron) loss seen in Parkinson’s. In 2019, Guttuso conducted a small pilot study to test this potential link in people with Parkinson’s. The results suggested that lithium had a positive effect on trial participants. As such, in 2022, low-dose lithium was prioritized by the International Linked Clinical Trials (iLCT) program — a drug development initiative set up in partnership between Cure Parkinson’s and VAI to support the clinical evaluation of drugs with the potential to slow, stop or reverse Parkinson’s progression."
Written by
Bolt_Upright
To view profiles and participate in discussions please or .
Seems to be a good podcast that explains some details: The Promise of Lithium as a Parkinson’s Disease Modifying Treatmentyoutu.be/1uOPS-1jOXU?si=oux...
I take 30 mg every morning. I figure the low dose, 15 mg, did not move the biomarkers, and the medium dose, 45 mg, did move the biomarkers, so I decided to go for the middle. I may increase this eventually.
Thanks for your post Bolt, very informative. Lithium orotate is in my husbands stack of supplements, so hoping it helps. He’s been taking it for quite a while now. It was mentioned on here before, and also on a post yesterday. it. It was also mentioned by Laura Mischley in her presentation, on No Silver Bullet, recently.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.